On March 3, 2011, Gradl, Stefan; Laird, Ellen; Moreno, David; Ren, Li; Wenglowsky, Steven Mark published a patent.Name: (6-(Trifluoromethyl)pyridin-3-yl)methanol The title of the patent was Preparation of 1H-pyrazolo[3,4-b]pyridine compounds useful for inhibiting Raf kinase. And the patent contained the following:
Title compounds I [R1 = H, halo, CN, etc.; R2 and R3 independently = H, halo, alkyl or alkoxy; R4 and R5 independently = H, halo or alkyl; R6 = (un)substituted Ph, 5- to 6-membered heteroaryl, 9- to 10-membered bicyclic heterocyclyl or heteroaryl; R7 = H or methyl], and their stereoisomers, tautomers or pharmaceutically acceptable salts, are prepared Thus, e.g., II was prepared by cyclization of 5-methoxy-1H-pyrazol-3-amine with sodium nitromalonaldehyde monohydrate followed by reduction and acylation with 3-(benzyloxy)benzoic acid. Compounds of the invention were evaluated for their inhibitory activity of human recombinant B-Raf protein and were found to have an IC50 value of < 1 μM. Methods of using such compounds for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders including cancer in mammalian cells, or associated pathol. conditions are disclosed. The experimental process involved the reaction of (6-(Trifluoromethyl)pyridin-3-yl)methanol(cas: 386704-04-7).Name: (6-(Trifluoromethyl)pyridin-3-yl)methanol
The Article related to pyrazolopyridine preparation raf kinase inhibitor cancer, Heterocyclic Compounds (One Hetero Atom): Pyridines and other aspects.Name: (6-(Trifluoromethyl)pyridin-3-yl)methanol
Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts